Marshall Wace North America’s 10x Genomics TXG Stock Holding History

Marshall Wace North America’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-58,409	Closed	-$8.27M	–	1787
2020 Q4	$8.27M	Buy	+58,409	New	+$8.48M	0.04%	423
2020 Q2	–	Sell	-30,024	Closed	-$1.87M	–	1486
2020 Q1	$1.87M	Buy	+30,024	New	+$2.34M	0.01%	498
2019 Q4	–	Sell	-28,994	Closed	-$1.46M	–	1612
2019 Q3	$1.46M	Buy	+28,994	New	+$1.6M	0.01%	612

Other funds holding TXG

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

MCAV

Meritech Capital Associates V Palo Alto, California $141M AUM 15.44% 1-Year Est. Return

1WCM

12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Marshall Wace North America's TXG Position: Q1 2021 in Review

Marshall Wace North America sold out of 10x Genomics (TXG) in Q1 2021, closing a stake of 58,409 shares — an estimated $8.27M sold.

Marshall Wace North America first reported a position in TXG in Q3 2019 and held it in 3 quarters. The position peaked at $8.27M in Q4 2020. 324 funds tracked by Wall St. Rank hold TXG as of Q1 2021.

Marshall Wace North America reported no remaining 10x Genomics position as of Q1 2021 after selling out during the quarter.
Marshall Wace North America sold 58,409 10x Genomics shares in Q1 2021, an estimated $8.27M.
Marshall Wace North America first reported a position in 10x Genomics in Q3 2019 and held it in 3 quarters.
Marshall Wace North America's 10x Genomics position peaked at $8.27M in Q4 2020.
324 funds tracked by Wall St. Rank held 10x Genomics as of Q1 2021.

Based on Marshall Wace North America's 13F filing for Q1 2021, filed 17 May 2021.